High-risk disease has worse prognosis irrespective of surgery type.
The accuracy was highest for type 1 cancer and hyperplasia.
Findings from phase 1/2 CheckMate 358 study.
FDA also approved companion test based on randomized, phase 3 PAOLA-1 trial.
A report by the IQVIA Institute for Human Data Science.
The survival was comparable to radical hysterectomy and radiotherapy.
A systematic review and meta-analysis of published studies.
A report by the IQVIA Institute for Human Data Science.
The approval was based on phase 3 PRIMA trial.
The enhancement of HPV-specific T cell-responses can potentiate the effect of the anti-PD-1 therapy in heavily pre-treated patients
An analysis of data from 13 NHS Trusts in England, Wales, and Scotland
Results from the UK Biobank.
Adjusting for site and stage eliminate the link between chemotherapy and stroke.
Shows superior survival in phase 3 AGO-OVAR 2.21 study.
The response is not durable in most patients, and further exploration is warranted.
There is evidence of worse oncologic outcomes associated with minimally-invasive radical hysterectomy, particularly with tumours >2 cm.
Fewer than 3 months of breastfeeding per child confers benefit.
